Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 2Cholangiocarcinoma 2Acrocephalosyndactylia 2Urinary Bladder Neoplasms 1Upper Tract Urothelial Carcinomas 1Tumor With Alterations of the FGF-R 1Melanoma 1Lung Neoplasms 1Hematologic Neoplasms 1Glioblastoma 1Central Nervous System Neoplasms 1Breast Neoplasms 1

Interventions

Capecitabine 77pembrolizumab 70Oxaliplatin 68Cisplatin 56Fluorouracil 52Paclitaxel 41Trastuzumab 37Nivolumab 35Leucovorin 27Docetaxel 27Irinotecan 22Ramucirumab 20Gemcitabine 15Bevacizumab 15S 1 (combination) 14Carboplatin 13atezolizumab 12apatinib 12fludarabine 11Cyclophosphamide 11tislelizumab 10Drug Therapy 10Injections 8130-nm albumin-bound paclitaxel 8trastuzumab deruxtecan 7durvalumab 7Ipilimumab 7Folfox protocol 7Albumin-Bound Paclitaxel 7titanium silicide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Stomach Neoplasms × infigratinib × Clear all
NCT06206278 2024-08-14

Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

LianBio LLC

Phase 2 Terminated
6 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05019794 2022-06-27

FGFR

LianBio LLC

Phase 2 Unknown
80 enrolled
Gastrointestinal

Acrocephalosyndactylia, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡